Oncology

The indication is for adjuvant treatment of adults with high-risk clear cell renal cell carcinoma (RCC) following nephrectomy, based on LITESPARK-022 showing a significant improvement in disease-free survival.

This week's episode covers the first-ever joint guidelines for cardiovascular-kidney-metabolic syndrome, key highlights from ASCO 2026 and ADA 2026, and new FDA approvals in diabetes, infectious diseases, and pain management.

Mayo Clinic tackles medication shortages with batching and fair overtime, keeping oncology acetaminophen available in a Pharmacy Times peer review.

MRD monitoring detects microscopic disease levels to guide treatment decisions, providing actionable insights for pharmacists.

A reflection from HOPA 2026 explores medical misinformation and how oncology pharmacists can strengthen trust and guide evidence-based patient care.

New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.

Phase 3 frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Skin Cancer Awareness Month in May spotlights oncology pharmacists driving prevention, innovative care, and supply-chain resilience built on patient trust.

Time to next treatment (TTNT) is an emerging real-world end point in CAR T-cell therapy that reflects treatment durability, clinical outcomes, and health care system factors beyond traditional efficacy measures.

Infection following CAR T-cell therapy is a common and clinically significant complication driven by prolonged immune dysregulation, cytopenias, and hypogammaglobulinemia, requiring phase-based risk awareness and proactive preventive management across the treatment continuum.

Vince Sung, PharmD, MBA, BCOP, BCPS, discusses the clinical implications of the updated prostate cancer guidelines.

A panel of clinical pharmacists meets to discuss the complex process of operationalizing cell and gene therapy at an academic medical center.

Elranatamab monotherapy produced a 92% overall response rate and a 45% complete response rate in patients with high-risk smoldering multiple myeloma, supporting the potential of BCMA-directed bispecific antibody therapy as an early intervention strategy before progression to active disease.

Cross-trial data from more than 6000 administrations show that a subcutaneous isatuximab on-body injector was highly reliable and well tolerated.

Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.

IDEAL trial data show iberdomide quadruplet therapy drives high response rates and rising MRD negativity in newly diagnosed multiple myeloma.

Phase 3 MajesTEC-9 data show that teclistamab monotherapy significantly improved PFS, OS, and depth of response compared with standard PVd or Kd regimens.

Christine Barrett, PharmD, BCOP discusses key updates to the Systemic Treatment of Thyroid Cancer: ASCO Guideline.

Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.

Results from the SERENA-6 trial show that an early switch to the oral selective estrogen receptor degrader camizestrant combined with a CDK4/6 inhibitor improves progression-free survival 2, delays chemotherapy, and preserves quality of life.

The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).

Real-world evidence is helping improve HER2-low metastatic breast cancer care, identify treatment gaps, and better understand patient distress and outcomes.

A real-world study presented at ASCO 2026 found that early intravenous immunoglobulin administration within 4 weeks of starting talquetamab was associated with significantly lower infection rates and reduced 1-year mortality in patients with relapsed or refractory multiple myeloma.

Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.

Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval is on the horizon.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Findings from the SWOG S2001 trial show that pembrolizumab plus olaparib did not significantly improve progression-free survival compared with olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer harboring germline BRCA1/2 mutations.

Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.